Down 40% In 2022, Can Exact Sciences Recover In 2023?
Today, early detection of cancer is much more common than it was ten years ago. Exact Sciences ( NASDAQ:EXAS ) can't claim all the credit, but the non-invasive cancer tests it sells play an important role. About 4 million people will be screened for cancer by the company in 2021. Despite its product's large audience, … Read more